|
Synonyms: ABT-981 | E26.13-SS-X3 [6]
Compound class:
Antibody
Comment: Lutikizumab (ABT-981) is an investigational monoclonal antibody targeting IL-1α and IL-1β [6], designed using proprietary technology to create dual variable domain antibodies ('DVD-IgTM') [3]. DVD-Igs are single pharmaceutical agents capable of simultaneously targeting two mediators of disease. The unique feature of DVD-Igs is that each arm of the antibody contains two tandem variable domains, each capable of binding a different antigen (see Figure 2 in [6]).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| ABT-981 has reached Phase 2a clinical trial in patients with OA of the knee (NCT02087904) and hand (NCT02384538). Phase 1 satety and tolerability findings from NCT01668511 are published in [8]. |
| Mechanism Of Action and Pharmacodynamic Effects |
| IL-1 stimulates degradation of cartilage [1-2,7] and inhibits damage repair in osteoarthritis (OA) [4-5]. Agents which neutralise the activity of IL-1 would therefore be expected to ameliorate the effects of excessive IL-1 activity in OA patients. Antibodies offer the advantage of extended duration of action over smaller peptides like the IL-1 receptor antagonist, anakinra. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01668511 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee | Phase 1 Interventional | AbbVie | ||
| NCT02087904 | A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis | Phase 2 Interventional | AbbVie | ||
| NCT02384538 | A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis | Phase 2 Interventional | AbbVie | ||
